American College of Cardiology announces late-breaking research for ACC.24 in Atlanta
The American College of Cardiology (ACC) has shared a full list of the late-breaking clinical sessions scheduled for the group’s annual meeting, ACC.24.
ACC.24 will take place April 6-8 at the Georgia World Congress Center in Atlanta. Transcatheter aortic valve replacement (TAVR), antithrombotic therapies, GLP-1 agonists, medical imaging guidance and blood pressure control represent just some of the topics that will be covered during late-breaking presentations over the course of the three-day event
“ACC is excited to be showcasing the latest research in cardiovascular care at ACC.24 in Atlanta,” ACC Annual Scientific Session Chair Douglas Drachman, MD, told Cardiovascular Business. “This year’s scientific session isn’t to be missed.”
The full late-breaking science presentation schedule:
Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials
Saturday, April 6 / 9:30-10:30 a.m. ET / Main Tent (Hall B1)
- A Double-blind, Randomized Placebo Procedure-controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF: Principal Results From the RELIEVE-HF Trial. Presented by Gregg Stone.
- Empagliflozin After Acute Myocardial Infarction: Results of the EMPACT-MI Trial. Presented by Javed Butler.
- CSL112 (Apolipoprotein A-I) Infusions and Cardiovascular Outcomes in Patients With Acute Myocardial Infarction (ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results. Presented by C. Michael Gibson.
Featured Clinical Research I
Saturday, April 6 / 4:15 – 5:30 p.m. ET / Murphy Ballroom 4
- Comparison of an "Inclisiran First" Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial. Presented by Michael Koren,
- Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes. Presented by Brian A. Ference.
- Once-weekly Semaglutide in Patients With Heart Failure With Preserved Ejection Fraction, Obesity and Type 2 Diabetes: Main Results From the Step-HFpEF Dm Trial. Presented by Mikhail N. Kosiborod.
- Mandibular Advancement Device Versus CPAP For Blood Pressure Reduction in Obstructive Sleep Apnea and High Cardiovascular Risk─ A Randomized Clinical Non-inferiority Trial (CRESCENT trial). Presented by R. C. Lee.
- Remote Acute Assessment of Patients With High Cardiovascular Risk Post-acute Coronary Syndrome (TELE-ACS). Presented by Nasser S Alshahrani.
Late-Breaking Clinical Trials II
Sunday, April 7 / 8 – 9:15 a.m. ET / Main Tent (Hall B1)
- Effect of Gamification, Financial Incentives or Both Combined to Increase Physical Activity Among Patients With Elevated Risk For Major Adverse Cardiovascular Events. The Be Active Randomized Clinical Trial. Presented by Alexander Fanaroff.
- Zilebesiran in Combination With a Standard-of-care Antihypertensive in Patients With Inadequately Controlled Hypertension: Primary Results From the Phase 2 Kardia-2 Study. Presented by George L. Bakris.
- Efficacy and Safety of Olezarsen in Patients With Hypertriglyceridemia and High Cardiovascular Risk: Primary Results of the BRIDGE-TIMI 73a Trial. Presented by Brian Bergmark.
- Randomized, Double-blind, Placebo-controlled, Phase 3, Study to Evaluate Lerodalcibep Long-term Efficacy and Safety in Patients With, or at Very-high or High Risk, For Cardiovascular Disease on Stable Lipid-lowering Therapy. Presented by Eric Klug.
- Plozasiran (ARO-APOC3), An Investigational RNAi Therapeutic, Demonstrates Profound and Durable Reductions in APOC-3 and Triglycerides (TG) in Patients With Severe Hypertriglyceridemia (SHTG), SHASTA-2 Final Results. Presented by Daniel Gaudet
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials III
Sunday, April 7 / 9:45 – 11 a.m. ET / Main Tent (Hall B1)
- Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized Smart Trial. Presented by Howard C. Herrmann.
- Effect of Edetate Disodium Based Chelation Infusions on Cardiovascular Events in Post-MI Patients With Diabetes: The TACT2 Trial. Presented by Gervasio Lamas.
- Long-term Beta-blocker Treatment After Acute Myocardial Infarction and Preserved Left Ventricular Ejection Fraction: The REDUCE-AMI Trial. Presented by Troels Yndigegn.
- Percutaneous Transvalvular Micro-axial Flow Pump in Infarct Related Cardiogenic Shock: Results of the Danger-shock Trial. Presented by Jacob Eifer Møller.
- One-month Ticagrelor Monotherapy After PCI in Acute Coronary Syndromes: Principal Results From the Double-blind, Placebo-controlled Ultimate DAPT Trial. Presented by Gregg Stone.
Featured Clinical Research II
Sunday, April 7 / 12:15 – 1: 30 p.m. ET / Main Tent (Hall B1)
- Benzodiazepine-free Cardiac Anesthesia For Reduction of Postoperative Delirium (B-Free): A Multi-centre Randomized Cluster Crossover Trial. Presented by J. Spence.
- The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Study: A Randomized Evaluation of a Team-based Remote Education and Medication Management Program to Reduce CV and Kidney Risk. Presented by Alexander Blood.
- Improving Cardiac Rehabilitation Participation in Lower-socioeconomic Status Patients: Case Management Vs. Financial Incentives. Presented by Diann Gaalema.
- Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic (PRO-HF) Trial. Presented by Alexander Sandhu.
- Restrictive Versus Liberal Blood Transfusion Strategy in Type 1 Versus Type 2 Myocardial Infarction: A Prespecified Subgroup Analysis From the Myocardial Ischemia and Transfusion (MINT) Trial. Presented by Andrew DeFilippis.
Clinical and Investigative Horizons
Sunday, April 7 / 4:30 – 5:45 p.m. ET / Murphy Ballroom 4
- Health 360x Registry: Scalable Workforce For Equitable Access to Point of Care Decentralized Clinical Trials
- Prevalence of Cardiovascular Disease and Risk Factors Among National Football League Alumni and Their Family Members: Results From the Huddle Study
- Hózhó (Heart Failure Optimization at Home to Improve Outcomes): A Pragmatic Clinical Trial of Telephone-based Guideline-directed Medical Therapy Optimization in Navajo Nation
- Advancing Acute MI Care in Densely Populated LMICs: Innovative Standalone Chest Pain Units For Expedited Triage and Timely Management – A Role Model For Global Healthcare Systems
- A Clinical Trial to Evaluate the Influence of a Spirituality Intervention on Blood Pressure Control, Central Hemodynamics and Endothelial Function: The Feel Trial
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials IV
Monday, April 8 / 8:30 – 9:45 a.m. ET / Main Tent (Hall B1)
- A Selective Aldose Reductase Inhibitor (at-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
- Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results of IMPROVE-HCM
- Topical Tranexamic Acid to Reduce Seizures in Cardiac Surgery
- Preventing Cardiac Damage in Patients Treated For Breast Cancer and Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced Cardiotoxicity (PROACT)
- Outcomes After Technology Assisted Nonprescription Rosuvastatin Administration: The TACTiC Trial
Late-Breaking Clinical Trials V
Monday, April 8 / 11 a.m. – 12:15 p.m. ET / Main Tent (Hall B1)
- Coronary Sinus Reducer For the Treatment of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC)
- Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients at Low to Intermediate Risk: One Year Outcomes of the Randomized DEDICATE-DZHK6 Trial
- Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target Bp I Randomized Trial
- Preventive PCI or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques
- Comparison of Intravascular Ultrasound-guided Versus Angiography-guided Angioplasty For the Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease
Featured Clinical Research III
Monday, April 8 / 12:45 – 2 p.m. ET / Room B406A
- Fractional Flow Reserve-guided Complete or Culprit-only PCI in Patients With ST-elevation Myocardial Infarction
- A Multicenter Prospective Randomized Study Comparing the Incidence of Periprocedural Cerebral Embolisms Caused by Catheter Ablation of Atrial Fibrillation Between Cryoballoon and Radiofrequency Ablation
- Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli (the TRAVERSE Trial)
- Intravascular Ultrasound-guided Versus Angiography-guided Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Multicenter, Randomized, Blinded, IVUS-ACS Trial
- Protein and Exercise to Reverse Frailty in Older Men and Women Undergoing Transcatheter Aortic Valve Replacement: The PERFORM-TAVR Trial
Additional information about ACC.24 is available here.
Review just some of the in-person coverage Cardiovascular Business provided during ACC.23/WCC in New Orleans:
Day 1 at ACC.23 features late-breaking studies on bempedoic acid, tricuspid valve repair and statins
Day 2 at ACC.23 features late-breaking studies on TEER, TAVR, EHR alerts and much more
Day 3 at ACC.23 features late-breaking studies on pulsed-field ablation, other new technologies
Michael Walter, Managing Editor
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.